Perforin and Fas/Fas ligand-mediated cytotoxicity in acute and chronic woodchuck viral hepatitis.
The Fas ligand (FasL)/Fas and the perforin-granzyme cytotoxic pathways presumably play a central role in the development of hepatocellular injury in viral hepatitis. To recognize the potential contribution of FasL and perforin-based cell killing in hepadnaviral infection, we adopted a cytotoxic assay using murine Fas+ P815 and human Fas- K562 cells as targets. Freshly isolated peripheral blood mononuclear cells (PBMC) from woodchucks with newly acquired woodchuck hepatitis virus (WHV) infection (n = 6), with chronic WHV hepatitis (n = 9), and from healthy animals (n = 11) were used as effector cells. We have found that woodchuck lymphoid cells kill cell targets via both the FasL/Fas and the perforin death pathways. The contribution of Fas-dependent cytolysis was ascertained in blocking experiments with anti-Fas antibody and by incubation of PBMC with cyclohexamide to prevent de novo synthesis of FasL. The involvement of the perforin pathway was confirmed by treatment of K562 cells with colchicine to inhibit the microtubule-dependent perforin release. Comparative analysis showed that peripheral lymphoid cells from acute WHV hepatitis, but not those from chronic WHV infection, are more cytotoxic and that this increase seems to be entirely due to activation of perforin-mediated killing. The data indicate that acute infection in woodchucks is associated with the augmented capacity of lymphoid cells to elicit perforin-dependent killing, but in chronic infection, independent of the severity of liver disease and duration of chronicity, these cells have the same or lower cytotoxic potential as PBMC from healthy controls. These findings suggest a role for non-specific cellular immunity, presumably natural killer (NK) cells, in the control of early WHV infection and in the progression of chronic hepatitis.
Hodgson
P D
PD
Molecular Virology and Hepatology Research, Faculty of Medicine, HealthSciences Centre, Memorial University of Newfoundland, St. John's, Newfoundland, Canada.
Grant
M D
MD
Michalak
T I
TI
D000208:Acute Disease; D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology; D002460:Cell Line; D003601:Cytotoxicity Tests, Immunologic; D053222:Fas Ligand Protein; D005260:Female; D006509:Hepatitis B / Q000097:blood / Q000276:immunology; D006510:Hepatitis B Antibodies / Q000097:blood; D017919:Hepatitis B Virus, Woodchuck / Q000276:immunology*; D019694:Hepatitis B, Chronic / Q000097:blood / Q000276:immunology; D006801:Humans; D007111:Immunity, Cellular / Q000187:drug effects; D020014:K562 Cells; D007963:Leukocytes, Mononuclear / Q000187:drug effects / Q000276:immunology; D008297:Male; D008392:Marmota; D008562:Membrane Glycoproteins / Q000276:immunology* / Q000502:physiology*; D051379:Mice; D054353:Perforin; D010835:Phytohemagglutinins / Q000494:pharmacology; D052899:Pore Forming Cytotoxic Proteins; D013997:Time Factors; D019014:fas Receptor / Q000276:immunology / Q000502:physiology*
D000911:Antibodies, Monoclonal; C505661:FASLG protein, human; D053222:Fas Ligand Protein; C505658:Fasl protein, mouse; D006510:Hepatitis B Antibodies; D008562:Membrane Glycoproteins; D010835:Phytohemagglutinins; D052899:Pore Forming Cytotoxic Proteins; D019014:fas Receptor; D054353:Perforin